Novo Nordisk files for FDA approval of CagriSema, the first onceweekly combination of GLP‑1 and amylin analogues for weight management

18 December 2025 - – Today, Novo Nordisk announced the submission of a new drug application to the US FDA ...

Read more →

FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection

17 December 2025 - Today, the FDA approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech) for subcutaneous injection for adult ...

Read more →

FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer

17 December 2025 - Today, the FDA approved rucaparib (Rubraca, pharmaand) for adults with a deleterious BRCA mutation (germline and/or ...

Read more →

Vanda announces submission of biologics license application to the FDA for imsidolimab for the treatment of generalised pustular psoriasis

15 December 2025 - Vanda Pharmaceuticals today announced the submission of a biologics license application to the US FDA) for ...

Read more →

Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma

16 December 2025 - Approval based on SWIFT trials showing significantly lower rate of annualised asthma exacerbations in patients receiving depemokimab ...

Read more →

Aldeyra Therapeutics announces PDUFA extension of the new drug application of reproxalap for the treatment of dry eye disease

15 December 2025 - Aldeyra Therapeutics today announced that the US FDA has extended the PDUFA target action date for the ...

Read more →

Historic first in women's sexual health: FDA grants approval for Addyi (flibanserin) in post-menopausal women

15 December 2025 -  Sprout Pharmaceuticals today announced a monumental milestone for women's health: the US FDA has approved Addyi ...

Read more →

US FDA approves LIB Therapeutics’ Lerochol (lerodalcibep-liga) for adults with elevated LDL-cholesterol

15 December 2025 - Lerochol expected to be available in the US in spring 2026. ...

Read more →

Sentynl Therapeutics announces FDA acceptance of CUTX-101 NDA resubmission

15 December 2025 - Sentynl Therapeutics today announced that the US FDA has accepted the resubmission of its new drug ...

Read more →

FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer

15 December 2025 - Today, the FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) in combination with pertuzumab for the first-line ...

Read more →

US FDA approves Daybue STIX (trofinetide) for oral solution, a new powder formulation, for Rett syndrome

15 December 2025 - Neuren Pharmaceuticals today announced that its partner Acadia Pharmaceuticals has received US FDA approval of Daybue ...

Read more →

Milestone receives FDA approval of Cardamyst (etripamil) as first and only self-administered nasal spray for adults with paroxysmal supraventricular tachycardia

12 December 2025 - First FDA approved treatment in 30+ years for more than 2 million Americans with paroxysmal supraventricular tachycardia. ...

Read more →

FDA approves two oral therapies to treat gonorrhea

12 February 2025 - Approvals are for uncomplicated urogenital gonorrhea. ...

Read more →

BioCryst announces FDA approval of Orladeyo (berotralstat) oral pellets, first and only oral prophylactic treatment for patients with HAE aged 2 to <12 years

12 December 2025 - BioCryst Pharmaceuticals today announced that the US FDA has approved its new drug application for the ...

Read more →

FDA approves Uplinza for adults with generalised myasthenia gravis

11 December 2025 - Amgen today announced that the US FDA has approved Uplinza (inebilizumab-cdon) for the treatment of generalised myasthenia ...

Read more →